Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2016
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 11 Jun 2013 Planned initiation date changed from 1 Nov 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 15 Oct 2012 New trial record